Samarium-153-EDTMP biodistribution and dosimetry estimation.
about
Overview of samarium sm 153 lexidronam in the treatment of painful metastatic bone diseaseRe-HEDP : pharmacokinetic characterization, clinical and dosimetric evaluation in osseous metastatic patients with two levels of radiopharmaceutical doseThe role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancerWell-designed bone-seeking radiolabeled compounds for diagnosis and therapy of bone metastasesVaccines as monotherapy and in combination therapy for prostate cancer.Development of (166)Holmium-1,2 Propylene Di-amino Tetra (Methy1enephosphonicacid) as a Possible Bone Palliation AgentDosimetric considerations in radioimmunotherapy and systemic radionuclide therapies: a review.Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma.The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitorsA preclinical investigation of the saturation and dosimetry of 153Sm-DOTMP as a bone-seeking radiopharmaceuticalThe use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killingIn the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer.Strengths and Weaknesses of a Planar Whole-Body Method of (153)Sm Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional Dosimetry.Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challengesProduction, Quality Control and Biological Evaluation of (166)Ho-PDTMP as a Possible Bone Palliation Agent.Samarium-153-ethylene diamine tetramethylene phosphonate, a beta-emitting bone-targeted radiopharmaceutical, useful for patients with osteoblastic bone metastasesBone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases.Preparation, Biological Evaluation and Dosimetry Studies of 175Yb-Bis-Phosphonates for Palliative Treatment of Bone Pain.Comparative Therapeutic Efficacy of 153Sm-EDTMP and 177Lu-EDTMP for Bone Pain Palliation in Patients with Skeletal Metastases: Patients' Pain Score Analysis and Personalized Dosimetry.Metastatic Bone Pain Palliation using (177)Lu-Ethylenediaminetetramethylene Phosphonic Acid.Modeling the time dependent biodistribution of Samarium-153 ethylenediamine tetramethylene phosphonate using compartmental analysis.Production, quality control and pharmacokinetic studies of Ho-EDTMP for therapeutic applications.Stromal targeted therapy in bone metastatic prostate cancer: promise delivered.Comparison of Tc-99m MDP and Sm-153 EDTMP bone scan.The Level of Europium-154 Contaminating Samarium-153-EDTMP Activates the Radiation Alarm System at the US Homeland Security Checkpoints.Production, Quality Control and Pharmacokinetic Studies of (177)Lu-EDTMP for Human Bone Pain Palliation Therapy TrialsQuantitative Imaging for Targeted Radionuclide Therapy Dosimetry - Technical Review.Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy.EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides.
P2860
Q24546181-D6950A49-7105-44FD-9216-649BB85D7D52Q24796082-D96C49ED-F859-42D8-BB5F-14D219CEF3EDQ26823733-06EE9CD1-FC19-49E7-8BC2-E0463676A3C6Q27002591-273267A1-C8CC-4031-8F01-6D3DF9A3E5CEQ34039068-947463C3-B452-43B6-BD6D-792D3F4DE546Q34111220-EEFF5527-1053-49A7-BF52-9AC67D732FFBQ35582104-0D055F97-5739-4D1A-B964-511D33B3AD7AQ35792772-F4265C71-22AA-4C7D-A147-533F3DE6F197Q35975387-C2A5E443-7C59-4BE0-B606-EF35C742F412Q36074212-03813768-46B2-4BE0-838C-1F067DEBEEE7Q36126003-F9C97B49-AB17-4B09-B814-E8E58DAD0DC9Q36210670-36A09895-EB85-480D-BC5C-A4B51435AFE7Q36297804-5AC202D8-50F4-4519-B58E-A42ECBDBB7D6Q36326713-08CDBAC1-1E31-46A9-8348-BCE00F21CA31Q36978118-587FA535-D212-49B7-BC3F-E9524F5BD525Q37103630-22847DFC-37D7-463D-BA67-643BA85BBB6AQ38004275-E85A3CBC-2427-431E-A5FE-3378A58F05B0Q38283709-A29DEE4F-C755-4EAD-B672-934C3A575A84Q38784378-D15116CA-94C6-4847-988A-FE54B07B6073Q39187541-643A834C-313C-4250-8FCD-31BC034FF889Q40671776-92535618-F608-4D6A-B014-444CFEBB7B99Q41182893-31777A0B-96A8-4F13-80F7-5D6F57CFC0DCQ41930832-78B4F3AB-45E3-4A21-8643-A79CBE7F2EEFQ42133778-3F9F257B-75BD-429E-A71A-7C9DF99F8F2EQ42553058-F781CC5C-07AD-49BC-A77B-A5163C4BF31AQ42768410-BB5F5995-48FB-4759-BB1B-7220ED572133Q47124584-A863F1C6-D3C1-4ABA-89EC-B193DE5A7FCBQ48323116-961EAF5C-7A11-4B13-AA75-BE8F027F9472Q49908522-493B72B8-6412-4C71-BDFF-E401730BDC67
P2860
Samarium-153-EDTMP biodistribution and dosimetry estimation.
description
1993 nî lūn-bûn
@nan
1993 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Samarium-153-EDTMP biodistribution and dosimetry estimation.
@ast
Samarium-153-EDTMP biodistribution and dosimetry estimation.
@en
Samarium-153-EDTMP biodistribution and dosimetry estimation.
@nl
type
label
Samarium-153-EDTMP biodistribution and dosimetry estimation.
@ast
Samarium-153-EDTMP biodistribution and dosimetry estimation.
@en
Samarium-153-EDTMP biodistribution and dosimetry estimation.
@nl
prefLabel
Samarium-153-EDTMP biodistribution and dosimetry estimation.
@ast
Samarium-153-EDTMP biodistribution and dosimetry estimation.
@en
Samarium-153-EDTMP biodistribution and dosimetry estimation.
@nl
P2093
P1476
Samarium-153-EDTMP biodistribution and dosimetry estimation.
@en
P2093
Addison SJ
Appelbaum F
Hartnett S
Petersdorf S
P304
P407
P577
1993-07-01T00:00:00Z